Back to Clinical Trials

Brief Title: A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors

An Open-label, Safety and Tolerability Phase 1b Trial of CAN04, a Fully Humanized Anti-IL1RAP Monoclonal Antibody, and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors


  • Org Study ID: CAN04CLIN002
  • Secondary ID: N/A
  • NCT ID: NCT04452214
  • Sponsor: Cantargia AB


This study will consider the safety and effectiveness of a study drug, CAN04, in combination with pembrolizumab, in the treatment of incurable or metastatic non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma, urothelial cancer, or malignant melanoma. The study aims to establish a recommended dose of CAN04 in combination with the standard dose of pembrolizumab (Part 1), and in combination with pembrolizumab standard dose, and Standard of Care carboplatin and pemetrexed (Part 2 - subjects with stage IV, non-squamous metastatic NSCLC). CAN04, pembrolizumab. carboplatin and pemetrexed will be administered intravenously.

  • Overall Status
  • Start Date
    September 24, 2020
  • Phase
    Phase 1
  • Study Type


Primary Outcome 1 - Measure:

Primary Outcome 1 - Timeframe: N/A


  • Carcinoma
  • Non-Small-Cell Lung
  • Urothelial Carcinoma
  • Malignant Melanoma
  • Head and Neck Squamous Cell Carcinoma


Inclusion Criteria (Part 1):
* Subjects with metastatic or locally advanced, incurable non-small-cell lung cancer (NSCLC [adenocarcinoma, adenosquamous, or squamous]), head and neck squamous cell carcinoma (HNSCC), urothelial cancer, or malignant melanoma who have exhausted or declined available standard therapy.

- * Subjects progressing on previous treatment with a checkpoint inhibitor targeting thePD-1/PD-L1 pathway, alone or in combination with chemotherapy after previously having achieved stable disease or better and stayed on such therapy for ≥12 weeks.

- * Primary or metastatic lesion suitable for biopsy and willingness to undergo repeat biopsies as appropriate.

- * Willing and able to provide intravenous access for the administration of the study drug and for blood sampling/testing.
Inclusion Criteria (Part 2):
* Subjects with histologically confirmed non-squamous metastatic (stage IV) NSCLC, without option for locoregional treatment with curative intent.

- * Subjects who have not received prior systemic anti-cancer therapy for the locally advanced or metastatic NSCLC. Subjects who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of metastatic disease.

- * Ability to safety undergo pre-treatment (if no archival biopsy is available) and on-treatment tumor biopsies.

- * Subject consents to retrieval of archival tumor tissue for screening in case no fresh biopsy is performed during screening.

- * Willing and able to provide intravenous access for the administration of the study drug and for blood sampling/testing.
Exclusion Criteria (Parts 1 and 2):
* Subjects with NSCLC tumors with genetic alteration or mutation, for which FDA-approved targeted therapy is available.

- * Treatment with systemic anticancer treatments, investigational products, or major surgery within 4 weeks before first dose of study drug or 5 half-lives, whichever is shorter. Subjects should have recovered from previous treatment toxicity (except hair loss and peripheral neuropathy).

- * History of uncontrolled brain metastasis.

- * Subject has received extended field radiotherapy ≤4 weeks before the start of treatment (≤2 weeks for limited field radiation to alleviate symptoms), and who has not recovered from related side effects of such therapy (except for hair loss).

- * Subjects who have previously experienced an immune-related adverse event (irAE) to pembrolizumab, for which permanent discontinuation is required. Subjects without a formal contraindication due to previous irAE are not eligible if the AE has not resolved or requires steroids (>10 mg prednisone-equivalent per day) for ongoing management.

- * Subjects with active severe infection requiring oral antibiotics.

- * Clinical evidence of an active second invasive malignancy with the exception of stable prostate cancer on watchful waiting.

- * Uncontrolled or significant cardiovascular disease.

- * History of autoimmune disease requiring systemic immunosuppressive therapy (daily prednisone equivalent doses >10 mg/day).

- * HIV patients can be enrolled if the infection is adequately controlled.

- * Known bleeding disorder or coagulopathy. Subjects on stable anticoagulant therapy are allowed.

- * Known or suspected allergy to study treatment or related products.

- * Women who are pregnant or breastfeeding, or trying to become pregnant.

- * Patients with chronic viral hepatitis.
Exclusion criteria (Part 2):
* Previous therapy with immunotherapy (anti-PD-1, anti-PD-L1, and anti-PD-L2, anti-CTLA-4, or other approved or investigational checkpoint-inhibitors).

- * Subject is unable or unwilling to take folic acid or vitamin B12 supplementation.

- * Subject is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDS), other than an aspirin dose ≤ 1.3 g per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam).
Other protocol-defined inclusion/exclusion criteria may apply.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No


Name: Ignacio Garcia-Ribas, MD, PhD

Role: Study Director

Affiliation: Cantargia AB

Overall Contact

Name: N/A

Phone: N/A

Email: N/A


Facility Status Contact